Reuters Market Eye - Macquarie upgrades Cipla Ltd to "outperform" from "neutral" and raises its target price to 480 rupees from 400, saying the drugmaker's April-June earnings were "significantly above" their estimates.
Cipla on Saturday posted an 18.5 percent jump in April-June net profit to 4.75 billion rupees.
Macquarie slightly raises its earnings estimates for fiscal years 2014 and 2015 earnings.
"We believe acceleration in export sales and comfort around sustainability of margins should drive upside going forward," Macquarie says in a report dated Saturday.
Cipla shares ended up 1.5 percent after earlier rising as much as 4.8 percent.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app